St. Jude Care & Treatment

Menu

Close

Recruiting

GLOBOTRK: Entrectinib for Brain Tumors

About this study 

Tumors of the brain and spine in very young children are hard to treat. They are usually treated with surgery, chemotherapy, and radiation.  Some of these tumors have changes in genes or proteins (called mutations).

This study will test whether the drug entrectinib will work against high-grade gliomas and other central nervous system tumors that have genetic changes called NTRK or ROS1 fusions. Patients will have imaging scans to see how the tumor responds to the drug. The length of treatment on this study is 5 years.

Eligibility overview

  • Birth–3 years old
  • Newly diagnosed brain tumor that has the NTRK or ROS1 mutation
  • No previous cancer therapy

Request a referralLearn about clinical research

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.

Overview

Full title:

Phase 2 Study of Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age with NTRK1/2/3 or ROS1-fused CNS Tumors (GLOBOTRK)

Study goal:

To find out whether entrectinib is effective in treating brain tumors with NTRK or ROS1 fusions

Diagnosis:

High-grade glioma and other CNS tumors

Age:

Birth–3 years old

Clinical trials categories:

Childhood Cancer High-Grade Glioma Brain Tumors

For physicians and researchers

Patients accepted to St. Jude must be referred by a physician or other qualified medical professional. Learn how St. Jude can partner with you to care for your patient.

 

Learn more